Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER2/Neu Detection by Immunohistochemistry Optimization of In-house Protocols

HER2/Neu Detection by Immunohistochemistry Optimization of In-house Protocols TECHNICAL ARTICLE HER2/Neu Detection by Immunohistochemistry Optimization of In-house Protocols Hugo M. Lourenc¸o, HT,* Teresa P. Pereira, HT,* Ricardo R. Fonseca, MD,*w and Paula M. Cardoso, HT* behaves as unfavorable prognostic marker and predictor Abstract: The assessment of HER2/neu status is performed to of poorer response to therapy. The target monoclonal predict monoclonal antibody therapeutic (trastuzumab) respon- antibody therapy with trastuzumab for breast cancer siveness of invasive breast cancer. The determination is usually patients with HER2-amplified tumors has greatly performed by immunohistochemistry (IHC), using commercial increased interest on HER2 testing, with emphasis on kits approved by the Food and Drugs Administration (FDA) or methodology. by in-house protocols. The authors evaluated HER2 expression Currently, immunohistochemistry (IHC) and in situ using different IHC protocols, to obtain the most concordant hybridization (ISH) are the main techniques recommended results with the FDA-approved system. A tissue microarray for HER2 status determination. It is consensual that ISH paraffin block with 110 samples of several types of histologic is the ‘‘gold standard’’ method, owing to the absolute specimens was built. On the basis of commercially available kit numeric results obtained, in contrast with the semiquanti- HercepTest, several protocol steps modifications were made and tative evaluation by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

HER2/Neu Detection by Immunohistochemistry Optimization of In-house Protocols

Loading next page...
 
/lp/wolters-kluwer-health/her2-sol-neu-detection-by-immunohistochemistry-optimization-of-in-p2Umu5bN6v

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1541-2016
DOI
10.1097/PAI.0b013e318186f0dc
pmid
18971784
Publisher site
See Article on Publisher Site

Abstract

TECHNICAL ARTICLE HER2/Neu Detection by Immunohistochemistry Optimization of In-house Protocols Hugo M. Lourenc¸o, HT,* Teresa P. Pereira, HT,* Ricardo R. Fonseca, MD,*w and Paula M. Cardoso, HT* behaves as unfavorable prognostic marker and predictor Abstract: The assessment of HER2/neu status is performed to of poorer response to therapy. The target monoclonal predict monoclonal antibody therapeutic (trastuzumab) respon- antibody therapy with trastuzumab for breast cancer siveness of invasive breast cancer. The determination is usually patients with HER2-amplified tumors has greatly performed by immunohistochemistry (IHC), using commercial increased interest on HER2 testing, with emphasis on kits approved by the Food and Drugs Administration (FDA) or methodology. by in-house protocols. The authors evaluated HER2 expression Currently, immunohistochemistry (IHC) and in situ using different IHC protocols, to obtain the most concordant hybridization (ISH) are the main techniques recommended results with the FDA-approved system. A tissue microarray for HER2 status determination. It is consensual that ISH paraffin block with 110 samples of several types of histologic is the ‘‘gold standard’’ method, owing to the absolute specimens was built. On the basis of commercially available kit numeric results obtained, in contrast with the semiquanti- HercepTest, several protocol steps modifications were made and tative evaluation by

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Mar 1, 2009

There are no references for this article.